Journal
PSYCHIATRIC CLINICS OF NORTH AMERICA
Volume 33, Issue 1, Pages 181-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.psc.2009.12.001
Keywords
Pharmacogenetics; Pharmacogenomics; Antidepressants; Antipsychotics; Mood stabilizers; Genome-wide association study; Efficacy; Side effects
Categories
Funding
- NIMH NIH HHS [K01 MH072866, T32 MH014592, K01 MH072866-01, T32-MH14592] Funding Source: Medline
Ask authors/readers for more resources
Existing psychotropic medications for the treatment of mental illnesses, including antidepressants, mood stabilizers, and antipsychotics, are clinically suboptimal. They are effective in only a subset of patients or produce partial responses, and they are often associated with debilitating side effects that discourage adherence. There is growing enthusiasm in the promise of pharmacogenetics to personalize the use of these treatments to maximize their efficacy and tolerability; however, there is still a long way to go before this promise becomes a reality. This article reviews the progress that has been made in research toward understanding how genetic factors influence psychotropic drug responses and the challenges that lie ahead in translating the research findings into clinical practices that yield tangible benefits for patients with mental illnesses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available